Revelation Biosciences REVB 深 滬
等待開盤 05-22 09:30:00 美东时间
1.08
-0.010
-0.92%
華盛通- 最 高1.11
- 今 開1.08
- 成交量 1.75万股
- 最 低 1.07
- 昨 收 1.09
- 總市值 422.11万
- 52周最高 13.80
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 0.875
- 委 比 79.49%
- 總股本 390.84万
- 歷史最高 2276064.00
- 量 比 0.34
- 振 幅 3.67%
- 歷史最低 1.07
- 每 手 1
- 風險率 5.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
05-09 00:05
Revelation Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Revelation Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary Revelation Biosciences Inc REVB.OQ reported a quarterly adjusted loss of $2.71 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-25.32. T
05-08 11:48
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over losses of $(25.34) per
05-08 04:56
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30,
03-30 21:02
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients Revelation Biosciences presented additional PRIME Study analyses at AKI & CRRT 2026 on March 29, 2026, highlighting Gemini effects in stage 3-4 chronic kidney disease patients. Data showed Gemini normalized cellul
03-30 21:02
Revelation Biosciences Shareholders Approve Warrant Share Issuance
Revelation Biosciences ( ($REVB) ) has shared an announcement. On March 18, 202...
03-20 04:51
Revelation Biosciences reports FY results
Revelation Biosciences press release (REVB): FY net loss of $59.76. As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024...
02-27 20:02
Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over losses of $(59.76) per
02-27 05:49
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
01-29 23:14
